Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578367 | 0.88 | ERN1 (0.37) | ERN1PRKDCCA1CA2CA9 | |
| SCHEMBL3185596 | 0.83 | ERN1 (0.50) | ERN1CYP3A4TSHRTDP1PTPN1 | |
| SCHEMBL6556132 | 0.82 | ERN1 (0.42) | ERN1PRKDCCA1CA2CA9 | |
| SCHEMBL29921076 | 0.82 | ERN1 (0.42) | ERN1PRKDCCA1CA2CA9 | |
| SCHEMBL23890741 | 0.78 | ERN1 (0.31) | ERN1 | |
| SCHEMBL9947770 | 0.78 | ERN1 (0.46) | ERN1TDP1PRKDCALDH1A1 | |
| SCHEMBL17449171 | 0.78 | ERN1 (0.33) | ERN1CYP3A4PRKDC | |
| SCHEMBL21061499 | 0.78 | CA1 (0.33) | ERN1CA1CA2CA9DGAT1 | |
| SCHEMBL19209562 | 0.78 | MEN1 (0.37) | ERN1TDP1ALDH1A1 | |
| SCHEMBL16097126 | 0.78 | ERN1 (0.37) | ERN1PRKDCCA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-30 | — | — | US | disclosed |
| US-8420646-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PAH P&U LLC (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110092494-A1 | Tricyclic Tetrahydroquinoline Antibacterial Agents | PHARMACIA & UPJOHN COMPANY | 2011-04-21 | — | — | US | disclosed |
| EP-1551849-B1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20100022524-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-7605157-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-10-20 | — | — | US | disclosed |
| WO-2007086895-A9 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | PINNACLE PHARMACEUTICALS (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007086895-A2 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | PINNACLE PHARMACEUTICALS (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | disclosed |
| US-20020091118-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | disclosed |
| US-20020091119-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2002046167-A1 | BENZYL (IDENE)-LACTAMS AND THEIR USE AS 5HT1-RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-6403592-B1 | SEROTONIN REUPTAKE INHIBITORS | PFIZER INC | 2002-06-11 | — | — | US | disclosed |
| US-6380186-B1 | PSYCHOTHERAPEUTIC AGENTS | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | disclosed |
| EP-0929528-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998014433-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091118-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | ERN1 1764/4885CYP3A4 276/4885TSHR 3436/4885 |
| US-20020091119-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | ERN1 1764/4885CYP3A4 276/4885TSHR 3436/4885 |
| US-20110092494-A1 | Tricyclic Tetrahydroquinoline Antibacterial Agents | QTRT1, QTRT2, NQO2 | ERN1 1952/4885CYP3A4 115/4885TSHR 3316/4885 |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | ERN1 1705/4885CYP3A4 430/4885TSHR 3050/4885 |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | ERN1 1764/4885CYP3A4 276/4885TSHR 3436/4885 |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | ERN1 1567/4885CYP3A4 4167/4885TSHR 3560/4885 |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | ERN1 1764/4885CYP3A4 276/4885TSHR 3436/4885 |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | ERN1 1567/4885CYP3A4 4167/4885TSHR 3560/4885 |
| US-20100022524-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | QTRT1, QTRT2, NQO2 | ERN1 1952/4885CYP3A4 115/4885TSHR 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.